1Karsdal MA, Krarup H, Sand JM, Christensen PB, GerstoftJ, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB,Krag A. Review article: the efficacy of biomarkers in chronicfibroproliferative diseases - early diagnosis and prognosis, with liverfibrosis as an exemplar. Aliment Pharmacol Ther 2014; 40: 233-249[PMID: 24909260 DOI: 10.1111/apt.12820].
2Wynn TA. Common and unique mechanisms regulate fibrosis invarious fibroproliferative diseases. J Clin Invest 2007; 117: 524-529[PMID: 17332879 DOI: 10.1172/JCI31487].
3Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP.Assessment of fibrosis and cirrhosis in liver biopsies: an update.Semin Liver Dis 2011; 31: 82-90 [PMID: 21344353 DOI: 10.1055/s-0031-1272836].
4Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y,Poynard T. Biochemical markers of liver fibrosis in patients withhepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6].
5Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol(N Y) 2013; 9: 737-739 [PMID: 24764791].
6Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and itscomplications. Gastroenterology 2008; 134: 1715-1728 [PMID:18471549 DOI: 10.1053/j.gastro.2008.03.007].
7de Franchis R, Primignani M. Natural history of portalhypertension in patients with cirrhosis. Clin Liver Dis 2001; 5:645-663 [PMID: 11565135].
8Burroughs AK, McCormick PA. Natural history and prognosis ofvariceal bleeding. Baillieres Clin Gastroenterol 1992; 6: 437-450[PMID: 1421594].
9Krook H. Estimation of portal venous pressure by occlusive hepaticvein catheterization. Scand J Clin Lab Invest 1953; 5: 285-292[PMID: 13135422].
10Armonis A, Patch D, Burroughs A. Hepatic venous pressuremeasurement: an old test as a new prognostic marker in cirrhosis-Hepatology 1997; 25: 245-248 [PMID: 8985299 DOI: 10.1053/jhep.1997.v25.ajhep0250245].
